The clinical management of HIV-infected individuals is based on highly active antiretroviral combination therapy, which provides significant clinical benefit in most patients, but causes in a high proportion of them a metabolic syndrome that includes body fat redistribution, hypercholesterolemia, hypertriglyceridemia, and insulin resistance. These effects are particularly evident in patients treated with protease inhibitors. It is likely that the metabolic disorders related to anti-HIV treatment will eventually translate into an increased cardiovascular risk in patients submitted to such regimens.
Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents / M., Fantoni; C., Del Borgo; Autore, Camillo; Barbaro, Giuseppe. - In: ITALIAN HEART JOURNAL. - ISSN 1129-471X. - 3:5(2002), pp. 294-299.
Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
AUTORE, Camillo;BARBARO, Giuseppe
2002
Abstract
The clinical management of HIV-infected individuals is based on highly active antiretroviral combination therapy, which provides significant clinical benefit in most patients, but causes in a high proportion of them a metabolic syndrome that includes body fat redistribution, hypercholesterolemia, hypertriglyceridemia, and insulin resistance. These effects are particularly evident in patients treated with protease inhibitors. It is likely that the metabolic disorders related to anti-HIV treatment will eventually translate into an increased cardiovascular risk in patients submitted to such regimens.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
